Business expansion
Location of affected unit(s)
Palafolls, Castellanos de Moriscos and Almunia de Doña Godina
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.2 - Manufacture of pharmaceutical preparations

124 jobs
Number of planned job creations
Job creation
Announcement Date
6 September 2022
Employment effect (start)
6 September 2022
Foreseen end date
6 September 2024


Novartis is a Swiss multinational in the manufacture of pharmaceutical products sector. The company has announced an investment of more than 75 million euros by 2024 to improve the production and innovation capacity of its factories in Spain, with a total net employment creation of 124 new jobs. In particular, the company is expecting to invest more than 63 million euros in its Palafolls factory (Barcelona) to convert it into one of the company's two innovative antibiotic production centres in Europe. 84 new jobs will be created and the manufacturing capacity of the facility will increase by 150%, from 200 to 500 tonnes per year. 

In the field of nuclear medicine, Novartis will invest 12.9 million euros in an innovative facility in Castellanos de Moriscos (Salamanca) for the production of radioligands, which are medicines already used for the treatment of breast and prostate tumours, among others. The new factory will create at least 20 jobs.

Lastly, Novartis will also invest a further 1.5 million euros in the expansion of its plant in Almunia de Doña Godina (Zaragoza), which will multiply production capacity by five, double export capacity and create another 20 new jobs.

Currently, Novartis employs 2,037 people in Spain.



Eurofound (2022), Novartis, Business expansion in Spain, factsheet number 107408, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/107408.